Amarin's (AMRN) Vascepa Tracking Well 3-Months In; Investors Eye Tier 2 Designation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Amarin (AMRN) Vascepa Growth Continues; Sees Limited Negative Read-Through from Merck's HPS2-THRIVE
March 11, 2013 10:54 AM EDTMKM Partners commented on Amarin Corporation (NASDAQ: AMRN) Monday as Vascepa prescription continue to gain momentum although sales might fall below the consensus.
The firm notes that after eight weeks, Vascepa total weekly prescriptions increased to 1,017 for the week ending March 1 from 838 the week prior (up 21% week over week). Analyst Jon LeCroy said current growth continues, assuming a wholesale cost of $184 per prescription and a prescription under-reporting rate of 22%, that would... More
Amarin (AMRN) Vascepa Growth Continues; Sees Limited Negative Read-Through from Merck's HPS2-THRIVE
March 11, 2013 10:54 AM EDTMKM Partners commented on Amarin Corporation (NASDAQ: AMRN) Monday as Vascepa prescription continue to gain momentum although sales might fall below the consensus.
The firm notes that after eight weeks, Vascepa total weekly prescriptions increased to 1,017 for the week ending March 1 from 838 the week prior (up 21% week over week). Analyst Jon LeCroy said current growth continues, assuming a wholesale cost of $184 per prescription and a prescription under-reporting rate of 22%, that would... More
Amarin's (AMRN) Vascepa Prescriptions Rise 34% in Week 7
March 4, 2013 3:31 PM ESTAmarin (NASDAQ:... More
